Article
Urology & Nephrology
Ravi A. Madan, Fatima H. Karzai, Munjid Al Harthy, Daniel P. Petrylak, Joseph W. Kim, Philip M. Arlen, Inger Rosner, Marc R. Theoret, Lisa Cordes, Marijo Bilusic, Cody J. Peer, Nancy A. Dawson, Anna Couvillon, Amy Hankin, Moniquea Williams, Guin Chun, Helen Owens, Jennifer L. Marte, Min-Jung Lee, Yusuke Tomita, Akira Yuno, Jane B. Trepel, Sunmin Lee, Seth M. Steinberg, James L. Gulley, William D. Figg, William L. Dahut
Summary: The study evaluated the safety and efficacy of cabozantinib combined with docetaxel in mCRPC patients. Cabozantinib was found to be safely added to docetaxel treatment with potential enhanced efficacy. However, due to limited patient accrual, the phase 2 study was terminated early.
Article
Multidisciplinary Sciences
Atefeh Deris, Mahdi Sohrabi-Haghighat
Summary: Patients with mCRPC are classified into three groups based on their response to Abiraterone treatment: best responder, responder, and non-responder. Drug-resistant cells may hinder successful outcomes in the latter two groups. To overcome this challenge, a combination of Docetaxel and Abiraterone is proposed to control both the overall cancer cell population and the drug-resistant subpopulation. Evolutionary Game Theory (EGT) is used as a mathematical modeling approach to study the competition and evolution of mCRPC cancer phenotypes.
Article
Oncology
Orazio Caffo, Cinzia Ortega, Franco Nole, Donatello Gasparro, Claudia Mucciarini, Michele Aieta, Vittorina Zagonel, Roberto Iacovelli, Ugo De Giorgi, Gaetano Facchini, Antonello Veccia, Erica Palesandro, Elena Verri, Sebastiano Buti, Giorgia Razzini, Giovanni Bozza, Marco Maruzzo, Chiara Ciccarese, Giuseppe Schepisi, Sabrina Rossetti, Francesca Maines, Stefania Kinspergher, Lucia Fratino, Paola Ermacora, Maurizio Nicodemo, Monica Giordano, Donata Sartori, Daniela Scapoli, Roberto Sabbatini, Giovanni Lo Re, Franco Morelli, Alessandro D'Angelo, Isabella Vittimberga, Paolo Lippe, Francesco Carrozza, Caterina Messina, Luca Galli, Francesca Valcamonico, Camillo Porta, Giovanni Pappagallo, Massimo Aglietta
Summary: The combination of enzalutamide and docetaxel appears to be more clinically beneficial than docetaxel alone in previously untreated mCRPC patients, although serious adverse events were more frequent. The results suggest that first-line treatment with this combination could lead to additional clinical benefit when prompt and prolonged disease control is needed. However, caution should be exercised due to the study's phase II design and the lack of overall survival benefit.
EUROPEAN JOURNAL OF CANCER
(2021)
Article
Urology & Nephrology
David Lorente, Casilda Llacer, Rebeca Lozano, Guillermo de Velasco, Nuria Romero-Laorden, Miguel Rodrigo, Angel Sanchez-Iglesias, Carlos di Capua, Elena Castro, Carlos Ferrer, Alfredo Sanchez-Hernandez, David Olmos
Summary: This study validated the prognostic value of the Armstrong risk model in patients treated with first-line androgen receptor signaling inhibitors, showing that low-risk patients received the greatest benefit. Further research is needed to establish the role of Armstrong risk groups for treatment selection in mCRPC patients.
Review
Pharmacology & Pharmacy
Junru Chen, Yaowen Zhang, Xingming Zhang, Jinge Zhao, Yuchao Ni, Sha Zhu, Ben He, Jindong Dai, Zhipeng Wang, Zilin Wang, Jiayu Liang, Xudong Zhu, Pengfei Shen, Hao Zeng, Guangxi Sun
Summary: This study compares the efficacy and safety of systemic treatments in mCRPC patients who have failed docetaxel. The results suggest that enzalutamide may offer the most significant survival benefits and satisfying safety, while cabazitaxel is effective in post-docetaxel settings but associated with a high risk of SAEs.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Medicine, General & Internal
Mallika Marar, Qi Long, Ronac Mamtani, Vivek Narayan, Neha Vapiwala, Ravi B. Parikh
Summary: This study investigated the differences in outcomes between African American and non-Hispanic White men with metastatic castration-resistant prostate cancer (mCRPC) who received first-line abiraterone therapy. The results showed that African American men had a higher overall survival when receiving first-line abiraterone compared to non-Hispanic White men. However, there was a difference in outcomes between the two groups for first-line enzalutamide treatment.
Article
Urology & Nephrology
Giulia Baciarello, Remy Delva, Gwenaelle Gravis, Youssef Tazi, Philippe Beuzeboc, Marine Gross-Goupil, Emmanuelle Bompas, Florence Joly, Charlotte Greilsamer, Thierry Nguyen Tan Hon, Philippe Barthelemy, Stephane Culine, Jean Francois Berdah, Mathilde Deblock, Raffaele Ratta, Aude Flechon, Caroline Cheneau, Aline Maillard, Geraldine Martineau, Isabelle Borget, Karim Fizazi
Summary: The preference for cabazitaxel over docetaxel among chemotherapy-naive men with mCRPC is mainly driven by reduced fatigue and improved quality of life.
Article
Oncology
Judith Passildas-Jahanmohan, Jean-Christophe Eymard, Melanie Pouget, Fabrice Kwiatkowski, Isabelle Van Praagh, Laurent Savareux, Marc Atger, Xavier Durando, Catherine Abrial, Damien Richard, Angeline Ginzac Couve, Emilie Thivat, Brigitte Monange, Philippe Chollet, Hakim Mahammedi
Summary: Despite good compliance and verified absorption of curcumin, the study showed no significant difference in progression-free survival between the curcumin and placebo groups, as well as in the secondary endpoints such as PSA response rate, overall survival, and quality of life. Consequently, the study was discontinued due to lack of efficacy.
Article
Oncology
Nanwei Xu, Jinge Zhao, Fengnian Zhao, Haoyang Liu, Wenlian Yin, Sha Zhu, Ling Nie, Guangxi Sun, Linmao Zheng, Zhenhua Liu, Diming Cai, Junru Chen, Jindong Dai, Yuchao Ni, Zhipeng Wang, Xingming Zhang, Jiayu Liang, Yuntian Chen, Xu Hu, Xiuyi Pan, Xiaoxue Yin, Xudong Zhu, Yaowen Zhang, Zilin Wang, Yuhao Zeng, Minghao Wang, Pengfei Shen, Ni Chen, Hao Zeng
Summary: This study aimed to explore the predictive value of neuroendocrine differentiation (NED) in patients with metastatic castration-resistant prostate cancer (mCRPC) receiving abiraterone or docetaxel as first-line therapy. The results showed that NED was associated with shorter survival in both abiraterone and docetaxel treatment, suggesting that NED detection may help predict treatment outcomes and optimize treatment decisions for mCRPC patients.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
(2023)
Review
Pharmacology & Pharmacy
Yang Liu, Xianzhong Deng, Zhi Wen, Jing Huang, Chongjian Wang, Caixia Chen, Erhao Bao, Jiahao Wang, Xuesong Yang
Summary: This study aimed to comprehensively assess the efficacy of multiple treatment regimens for metastatic castration-resistant prostate cancer (mCRPC) through a network meta-analysis (NMA) of randomized controlled trials (RCTs). The results showed that chempretarget, PARP inhibitors, and chempre significantly improved survival outcomes for mCRPC patients. These findings have important implications for treatment decision-making in mCRPC and may guide the development of more effective therapeutic strategies.
FRONTIERS IN PHARMACOLOGY
(2023)
Article
Medicine, General & Internal
Oliver Sartor, Johann de Bono, Kim N. Chi, Karim Fizazi, Ken Herrmann, Kambiz Rahbar, Scott T. Tagawa, Luke T. Nordquist, Nitin Vaishampayan, Ghassan El-Haddad, Chandler H. Park, Tomasz M. Beer, Alison Armour, Wendy J. Perez-Contreras, Michelle DeSilvio, Euloge Kpamegan, Germo Gericke, Richard A. Messmann, Michael J. Morris, Bernd J. Krause
Summary: The radioligand therapy with Lu-177-PSMA-617 prolonged both imaging-based progression-free survival and overall survival in patients with PSMA-positive metastatic castration-resistant prostate cancer when added to standard care. Adverse events were more common with Lu-177-PSMA-617 but did not significantly impact quality of life.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Oncology
Rohan Garje, R. Bryan Rumble, Rahul A. Parikh
Summary: ASCO Rapid Recommendations Updates revise select ASCO guideline recommendations in response to new and practice-changing data, with the goal of disseminating updated recommendations in a timely manner to better inform health practitioners and the public on the best available cancer care options.
JOURNAL OF CLINICAL ONCOLOGY
(2022)
Article
Multidisciplinary Sciences
M. C. Cursano, V Conteduca, E. Scarpi, G. Gurioli, C. Casadei, S. Gargiulo, A. Altavilla, C. Lolli, B. Vincenzi, G. Tonini, D. Santini, U. De Giorgi
Summary: This study examined the association between GG score and AR CNV in mCRPC patients, finding that patients with GG5 and AR CNV gain have a worse prognosis, suggesting frontline docetaxel treatment may be more beneficial for them.
SCIENTIFIC REPORTS
(2022)
Review
Oncology
Irbaz Bin Riaz, Syed Arsalan Ahmed Naqvi, Huan He, Noureen Asghar, Rabbia Siddiqi, Hongfang Liu, Parminder Singh, Daniel S. Childs, Praful Ravi, Syed A. Hussain, Mohammad Hassan Murad, Stephen A. Boorjian, Christopher Sweeney, Eliezer M. Van Allen, Alan H. Bryce
Summary: This study aimed to assess the comparative effectiveness of contemporary systemic treatment options for patients with metastatic castration-sensitive prostate cancer (mCSPC) across clinically relevant subgroups. The results suggest that darolutamide (DARO) triplet and abiraterone (AAP) triplet are not associated with improved overall survival (OS) compared to androgen pathway inhibitor (API) doublets in the overall population. However, AAP + D + ADT may improve OS in high-volume disease patients.
Article
Oncology
Wei Ning, Pengkang Chang, Ji Zheng, Fan He
Summary: This case report highlights the potential effectiveness and safety of a second docetaxel rechallenge as a later-line treatment strategy for patients with mCRPC who are concerned about the high costs of multigene molecular testing and PARP inhibitors, as well as repeated prostate needle biopsy.
FRONTIERS IN ONCOLOGY
(2023)
